SNYSanofi
Price
-11%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth steady, the market undecided.
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
In the company’s own words · 20-F filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Sanofi (SNY) reported revenue of €23.7B in H2 2025 (quarter ended Dec 31, 2025), up 35% from the same quarter a year earlier. That came with a gross margin of 77% and net income of €2.00B (8.4% of revenue). For the full year FY2025, revenue was €43.6B (+6.2% year on year) and net income €7.81B.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
Ranks #7 of 7 by RyuScore